Showing 1 - 10 of 105
Persistent link: https://www.econbiz.de/10011005069
Persistent link: https://www.econbiz.de/10011005082
Background: Shared decision making is the process in which a healthcare choice is made jointly by the health professional and the patient. Little is known about what patients view as effective or ineffective strategies to implement shared decision making in routine clinical practice. Objective:...
Persistent link: https://www.econbiz.de/10011005085
Introduction: Standard methods of economic analysis may not be suitable for local decision making that is specific to a particular population. Background: We describe a new three-step methodology, termed `population cost-impact analysis', which provides a population perspective to the costs and...
Persistent link: https://www.econbiz.de/10005243055
This paper describes the key principles of why an assessment of uncertainty and its consequences are critical for the types of decisions that a body such as the UK National Institute for Health and Clinical Excellence (NICE) has to make. In doing so, it poses the question of whether formal...
Persistent link: https://www.econbiz.de/10005243089
Persistent link: https://www.econbiz.de/10005243098
Internationally, there has been a movement in medicine to better involve patients in decision making, whether it be at the individual or aggregate level. However, the German health sector has been slow to understand and accommodate the preferences of patients. This paper discusses the reasons...
Persistent link: https://www.econbiz.de/10005243132
Persistent link: https://www.econbiz.de/10005243170
Background:Background: The Common Drug Review (CDR) was created to provide a single process to review the comparative clinical efficacy and cost effectiveness of new drugs, and then to make formulary listing recommendations to Canadian publicly funded drug benefit plans. Abstract:...
Persistent link: https://www.econbiz.de/10009493382
Background:Background: In the Netherlands, decisions about the reimbursement of new pharmaceuticals are based on cost effectiveness, as well as therapeutic value and budget impact. Since 1 January 2005, drug manufacturers are formally required to substantiate the cost effectiveness of drugs that...
Persistent link: https://www.econbiz.de/10009493384